The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 21, 2022
Filed:
Aug. 04, 2017
Inserm (Institut National DE LA Sante ET DE LA Recherche Medicale), Paris, FR;
Medecine ET Innovation, Paris, FR;
Universite Paris Diderot—paris 7, Paris, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Daniel Zagury, Paris, FR;
Helene Le Buanec, Paris, FR;
Sophie Duchez, Paris, FR;
Valerie Schiavon, Paris, FR;
Armand Bensussan, Paris, FR;
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris, FR;
MEDECINE ET INNOVATION, Paris, FR;
UNIVERSITÉ PARIS DIDEROT—PARIS 7, Paris, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
Abstract
The present invention relates to a method for ex vivo generating and expanding MHCII restricted CD4Foxp3regulatory T cells, and therapeutic uses thereof. The inventors here demonstrated the optimal conditions for inducing Foxp3 expression in naive CD3+ CD4+ TCRαβ+ MHCII restricted T following polyclonal or following antigen-specific activation. They also developed an experimental procedure to generate autologous CD8+ T cell lines functionally committed to lyse tumor-antigen specific FOXP3 expressing TCRαβ+ MHCII restricted T cells, pathogenic CD4+ T cells that favour tumor cell immune evasion. In particular, the present invention relates to a method for generating ex vivo MHCII restricted CD4+ Foxp3+ regulatory T cells having the following phenotype: CD3+ CD4+ Foxp3+.